A Randomized Controlled Trail of Bacillus Calmette-Guerin and Botulinum Toxin-A for the Treatment of Refractory Interstitial Cystitis

Elbahnasy, Abdelhamid M.; Farahat, Yasser; El-Bendary, Mohamad; Taha, Mohamad R; El-Damhogy, Mahmoud; Mourad, Sherif

doi:10.3834/uij.1944-5784.2008.12.06

Cited by 14 publications

(41 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 3 months, there was a significant decrease in symptom indices, symptoms recorded in a bladder diary and urodynamic parameters with onabotulinumtoxinA compared with hydrodistention alone. The other level 2 study showed more improvement in frequency, nocturia and global IC score with 300 U of onabotulinumtoxinA compared with instillation of bacillus Calmette‐Guérin 111 . The level 1 study reported on QoL outcomes utilising the Chronic Prostatitis Symptom Index (female modification) and American Urological Association indices, as well as graded chronic pain, and perceived stress scales and the VAS; outcomes were not found to be significantly different from a placebo 109 .…”

Section: Therapeutic Effects Of Botox On Ic/pbsmentioning

confidence: 98%

“…Pilot studies reporting the efficacy of BoNT‐A for treating IC/PBS since 2004 have revealed controversial results 12,107,108 . However, most recent studies support the effects of BoNT‐A in patients with chronic IC/PBS 108–116 . All nine articles mentioned in Table 3 reporting the use of BoNT‐A for IC/PBS utilized onabotulinumtoxinA.…”

Section: Therapeutic Effects Of Botox On Ic/pbsmentioning

confidence: 99%

“…12,107,108 However, most recent studies support the effects of BoNT-A in patients with chronic IC/PBS. [108][109][110][111][112][113][114][115][116] All nine articles mentioned in Table 3 reporting the use of BoNT-A for IC/PBS utilized onabotulinumtoxinA. Of these, one study was level 1 and two were level 2.…”

Section: Efficacy Of Bont-a On Ic/pbsmentioning

confidence: 99%

See 2 more Smart Citations

Botulinum toxin injection for lower urinary tract dysfunction

Kuo

2012

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms 5ARI = 5-alpha-reductase inhibitor Ach = acetylcholine AD = autonomic dysreflexia ATP = adenosine triphosphate BCG = bacillus Calmette-Guérin BoNT = botulinum toxin BoNT-A = botulinum toxin type A BOO = bladder outlet obstruction BPH = benign prostatic hyperplasia CGRP = calcitonin gene-related peptide Abstract: Botulinum toxin has been recently accepted as a novel treatment for lower urinary tract dysfunctions refractory to conventional treatment. Review of the clinical trials in recent years, botulinum toxin type A has been widely used in the urethra or urinary bladder to treat voiding dysfunction due to detrusor sphincter dyssynergia, incontinence due to neurogenic or idiopathic detrusor overactivity, sensory disorders such as bladder hypersensitivity, overactive bladder, and interstitial cystitis/painful bladder syndrome. Intravesical botulinum toxin type A injection is effective in treatment of urinary incontinence due to detrusor overactivity in men and women, as well as in children. Currently botulinum toxin type A has also been applied to treat lower urinary tract symptoms due to benign prostatic hyperplasia in patients not suitable for surgery. This article reviewed the recent advances of botulinum toxin type A on lower urinary tract dysfunction.

show abstract

Section: Therapeutic Effects Of Botox On Ic/pbsmentioning

confidence: 98%

Section: Therapeutic Effects Of Botox On Ic/pbsmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum toxin injection for lower urinary tract dysfunction

Kuo

2012

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…However, BoNTA showed no treatment advantages with regard to pain, urinary frequency, and urgency results. In one trial, BoNTA showed a significant treatment effect on pain, urinary frequency, and urgency compared with BCG, but these findings require further research for confirmation [45]. The mechanism of BCG in IC/PBS treatment remains unclear though it may be related to local immune system impairment [28].…”

Section: Discussionmentioning

confidence: 99%

“…One study had a three-arm design, and included 0.05 μM RTX, 0.1 μM RTX, and placebo control groups [38]; another study had a four-arm design, and included 0.01 μM RTX, 0.05 μM RTX, 0.1 μM RTX, and placebo control groups [39]. Five studies identified additional treatments in both groups, including hydrodistention [8,37], oral PPS [5,41], and antibiotics [45]. The shortest and longest follow-up times were 29 days and 24 months respectively (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis

et al. 2016

View full text Add to dashboard Cite

Introduction and hypothesis Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic inflammatory condition of the submucosal and muscular layers of the bladder. So far, there is no effective and targeted treatment strategy for IC/ PBS. This study aimed to assess the efficacy and safety of intravesical instillation treatment in IC/PBS patients. Methods We searched various databases up to October 2015. A network meta-analysis was performed to compare global response assessment (GRA) for different treatment strategies, including botulinum toxin A (BoNTA), bacillus CalmetteGuerin (BCG), resiniferatoxin (RTX), lidocaine, chondroitin sulfate (CS), oxybutynin, and pentosan polysulfate (PPS). A traditional meta-analysis was also performed. Results Sixteen trials evaluating 905 patients were included. Network meta-analysis indicated that BoNTA had the highest probability of being the best treatment course according to GRA assessment results (probability 81.7 %). BCG or BoNTA therapy yielded significant improvement in GRA incidence according to traditional meta-analysis. Patients who received PPS showed higher urinary frequency results compared with the placebo groups. BCG-and PPS-treated patients had elevated urinary urgency treatment effects compared with placebo groups. Bladder capacity restoration results also showed significant improvements in patients who received BoNTA compared with placebo-treated individuals. Conclusions These findings indicate that BoNTA therapy has the highest probability of being the best therapy according to GRA, and significantly improves bladder capacity in IC/PBS patients. BCG treatment also significantly increases the incidence of GRA and improves the symptoms of urinary urgency. PPS can significantly improve urinary frequency and urgency symptoms in IC/PBS patients.

show abstract

Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine

Vijayakumar

Jankovic

2020

Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine

View full text Add to dashboard Cite

A Randomized Controlled Trail of Bacillus Calmette-Guerin and Botulinum Toxin-A for the Treatment of Refractory Interstitial Cystitis

Cited by 14 publications

References 19 publications

Botulinum toxin injection for lower urinary tract dysfunction

Botulinum toxin injection for lower urinary tract dysfunction

Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis

Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine

Contact Info

Product

Resources

About